AU2023240100A1 - Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof - Google Patents

Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof Download PDF

Info

Publication number
AU2023240100A1
AU2023240100A1 AU2023240100A AU2023240100A AU2023240100A1 AU 2023240100 A1 AU2023240100 A1 AU 2023240100A1 AU 2023240100 A AU2023240100 A AU 2023240100A AU 2023240100 A AU2023240100 A AU 2023240100A AU 2023240100 A1 AU2023240100 A1 AU 2023240100A1
Authority
AU
Australia
Prior art keywords
crystalline form
peaks
exhibits
compound
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023240100A
Other languages
English (en)
Inventor
James Abellera BLAIR
Neil Sonin DHAWAN
Meiqi LI
Robert B Perni
Jared Lynn Randall
Xiaoyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Totus Medicines Inc
Original Assignee
Totus Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Totus Medicines Inc filed Critical Totus Medicines Inc
Publication of AU2023240100A1 publication Critical patent/AU2023240100A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023240100A 2022-03-24 2023-03-24 Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof Pending AU2023240100A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/082752 2022-03-24
CN2022082752 2022-03-24
PCT/CN2023/083760 WO2023179771A1 (en) 2022-03-24 2023-03-24 Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2023240100A1 true AU2023240100A1 (en) 2024-10-03

Family

ID=86286092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023240100A Pending AU2023240100A1 (en) 2022-03-24 2023-03-24 Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Country Status (8)

Country Link
US (1) US20250197408A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499642A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509950A (cg-RX-API-DMAC7.html)
KR (1) KR20250044815A (cg-RX-API-DMAC7.html)
CN (1) CN119212996A (cg-RX-API-DMAC7.html)
AU (1) AU2023240100A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246202A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023179771A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154079A1 (en) 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154079A1 (en) 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates

Also Published As

Publication number Publication date
US20250197408A1 (en) 2025-06-19
KR20250044815A (ko) 2025-04-01
CA3246202A1 (en) 2023-09-28
WO2023179771A1 (en) 2023-09-28
EP4499642A1 (en) 2025-02-05
JP2025509950A (ja) 2025-04-11
CN119212996A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
TWI921632B (zh) Kras抑制劑的多晶型物及其製備方法和用途
AU2019303777B2 (en) Salt of LSD1 inhibitor and a polymorph thereof
KR20170032330A (ko) C-Met 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
AU2020328534B2 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
CN110678178A (zh) Mk2抑制剂的形式和组合物
JP7802200B2 (ja) 置換のアミノ6員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
CN110577543B (zh) 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
WO2023179771A1 (en) Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
BR112018016708B1 (pt) Compostos de 7h-pirrolo[2,3-d]pirimidina e processo para preparar os ditos compostos
CN108778282B (zh) 一种GnRH受体拮抗剂的结晶形式及其制备方法
CN108368061A (zh) 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物的固体形式
WO2025085766A1 (en) Crystalline forms of fumarate salt of mrtx0902
JP2025541854A (ja) カンプトテシン誘導体、医薬組成物及びその製造方法と使用
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
US20230121346A1 (en) The salts of a compound and the crystalline forms thereof
WO2022099442A1 (zh) 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
WO2026026904A1 (en) The crystalline forms of a compound
HK40072576B (en) Compound used as kinase inhibitor and use thereof
WO2025256556A1 (zh) Protac嵌合化合物的固体形式、其制备方法、药物组合物和用途
WO2025085791A1 (en) Crystalline forms of mrtx0902
WO2025256557A1 (zh) Protac嵌合化合物的药学上可接受的盐及其结晶形式、其制备方法、药物组合物和用途
HK40117473A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
CN120813579A (zh) 大环类化合物的合成及其在医药上的用途
WO2019091400A1 (zh) 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN111825690A (zh) 一种phd抑制剂的新晶型及其制备方法